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Abstract
Background: Thiazide diuretics have demonstrated favorable blood pressure lowering efficacy, but the equivalent
doses of their more common agents, chlorthalidone and hydrochlorothiazide, are still unclear. Further, concerns
exist regarding adverse metabolic effects, which may be attenuated with the concomitant administration of a
potassium-sparing diuretic, such as amiloride. This trial aims to investigate the efficacy of chlorthalidone and
hydrochlorothiazide, in combination with amiloride at different doses, for initial management of patients with
primary hypertension.
Methods/design: This is a factorial (2 × 2) randomized double-blinded clinical trial comparing the association of a
thiazide diuretic (chlorthalidone 25 mg/day or hydrochlorothiazide 50 mg/day) with a potassium-sparing diuretic
(amiloride 10 mg/day or amiloride 20 mg/day) in patients with primary hypertension. The primary outcome will be
the mean change from baseline in 24-h systolic and diastolic blood pressure measured by ambulatory blood
pressure monitoring. The secondary outcomes will be the mean change from baseline in daytime and nighttime
systolic and diastolic blood pressure measured by ambulatory blood pressure monitoring, mean change from
baseline in systolic and diastolic blood pressure measured by office blood pressure, incidence of adverse events,
variation of laboratory parameters, and proportion of patients who achieved blood pressure control. The follow-up
will last 12 weeks. For a P alpha of 0.05, power of 80%, standard deviation of 9 mmHg, and absolute difference of 6
mmHg on systolic blood pressure on 24-h ambulatory blood pressure monitoring, it will be necessary to study a
total of 76 patients. The sample size will be increased by 10% to compensate for losses, resulting in 84 patients
being randomized.
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Discussion: Diuretics are pivotal drugs for the treatment of hypertension. Chlorthalidone and hydrochlorothiazide,
in combination with amiloride in multiple doses, will be tested in terms of blood pressure lowering efficacy and
safety. Since the intensity of blood pressure reduction is the major determinant of reduction in cardiovascular risk in
hypertensive patients, this study will help to determine which combination of diuretics represents the most appropriate
treatment for this population.
Trial registration: ClinicalTrials.gov, NCT03928145. Registered on 25 April 2019. Last update on 29 April 2019.
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Background
Thiazide diuretics have been commonly used as pharmaco-
logical agents for the treatment of hypertension for over five
decades [1, 2], remaining the cornerstone of antihypertensive
treatment due to their favorable blood pressure (BP) lower-
ing efficacy, safety profile, and low cost. In patients with pri-
mary hypertension, thiazide diuretics have been
demonstrated to be effective at low doses [3–10], while
higher doses produce more side effects, often with little fur-
ther reduction in BP [4]. Chlorthalidone (CTD) has been
shown to provide greater antihypertensive efficacy than hy-
drochlorothiazide (HCTZ) at similar dose levels [11–15] with
no evidence of higher incidence of side effects [15]. CTD is
1.5 to 2 times as effective as HCTZ at lowering BP at the
same dose [12]. The smaller efficacy of HCTZ may be ex-
plained by a shorter duration of action compared to CTD
[11, 12, 16]. Thus, when compared to HCTZ, these charac-
teristics of CTD could promote better results in reducing BP
and cardiovascular outcomes [17].
The use of thiazide diuretics may be associated with
adverse metabolic effects, such as hypokalemia, hypona-
tremia, hyperuricemia, hyperglycemia, hyperlipidemia,
and hypomagnesemia [4, 18, 19]. The incidence of these
metabolic complications increases in a dose–response
manner [3, 4, 20, 21]. It is estimated that less than half
of the patients receiving thiazide diuretics develop hypo-
kalemia (serum potassium < 3.5 mEq/L) [22]. The benefi-
cial effect of chlorthalidone in the prevention of major
cardiovascular events in the SHEP trial was lost when
potassium dropped below 3.5 mEq/L [23]. The risk of
hypokalemia may be minimized by combining thiazides
with blockers of the epithelial sodium channel (e.g.,
amiloride and triamterene), which may also mitigate the
impaired glucose tolerance associated with thiazides
[24]. The blockers of the epithelial sodium channel are
commonly referred to as potassium-sparing diuretics.
Although the antihypertensive properties of the thiazide
diuretics have been well documented [3–10], the BP
lowering effect of potassium-sparing diuretics has not
been as clearly determined [25]. However, some studies
suggest that amiloride may be valuable in treating resist-
ant hypertension [26] and may have a more potent anti-
hypertensive effect in higher doses [24, 27].
It remains unknown whether different diuretics are as-
sociated with different clinical outcomes. Both CTD and
indapamide have been shown to reduce cardiovascular
events in landmark randomized trials [28, 29], whereas
there is no evidence that HCTZ alone reduces cardiovas-
cular events [30]. Despite opinions on the preference of
CTD and indapamide over classic thiazide diuretics (e.g.,
HCTZ) [31], no randomized controlled trials have directly
compared HCTZ versus CTD in relation to cardiovascular
outcomes in hypertensive patients. This scenario supports
the relevance of comparative testing of these drugs. Sub-
stantial clinical evidence concluded that the amount of BP
reduction is the major determinant of reduction in cardio-
vascular risk in hypertensive patients [21, 32–34], which
renders the BP lowering effect among diuretics an appro-
priate surrogate outcome.
So, we designed a factorial trial to compare the BP-
lowering efficacy and safety profile of CTD and HCTZ, in
combination with amiloride in multiple doses, in patients
with primary hypertension. The mean change from base-
line in 24-h systolic and diastolic BP measured by ambula-
tory blood pressure monitoring (ABPM) is the primary
outcome. The mean change from baseline in daytime and
nighttime systolic and diastolic BP measured by ABPM,
mean change from baseline in systolic and diastolic BP
measured by office BP, incidence of adverse events, vari-
ation of laboratory parameters, and proportion of patients
who achieved BP control are the secondary outcomes.
Primary objectives
To compare CTD 25mg with amiloride 20 mg versus
other combinations of thiazide with amiloride, with re-
spect to BP-lowering efficacy, in subjects with primary
hypertension.
Secondary objectives
To compare, in subjects with primary hypertension,
CTD 25mg with amiloride 20 mg versus other combina-
tions of thiazide with amiloride, with respect to the inci-
dence of adverse events, variation of laboratory
parameters, and proportion of patients who achieved BP
control.
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Methods/design
Study design
This is a randomized double-blind single-center super-
iority trial, controlled by active treatment, with factorial
design (2 × 2), with a 1:1:1:1 allocation ratio, follow-up
period of 12 weeks, and a primary endpoint of mean
change from baseline in 24-h systolic and diastolic BP
measured by ABPM. Eligible participants will be ran-
domized to receive two simultaneous interventions: a
thiazide diuretic (CTD 25mg/day or HCTZ 50mg/day)
and a potassium-sparing diuretic (amiloride 10mg/day
or amiloride 20mg/day).
Study setting
The study will be conducted in the Center for Clinical
Research of Hospital de Clínicas de Porto Alegre
(HCPA), which aims to establish guidelines and policies
regarding the conduct of clinical research as a whole. In
this sense, it provides adequate infrastructure for the de-
velopment of all stages of clinical and epidemiological
studies, in line with the public health needs of Brazil.
Inclusion criteria:
 Adults (aged 30 to 75 years) with diagnosis of
primary hypertension based on ABPM (mean 24-h
systolic BP ≥ 130 mmHg or mean 24-h diastolic BP
≥ 80mmHg)
 No current use of antihypertensive medication
 Written consent for participation in the study
If the patient is on antihypertensive monotherapy prior
to randomization and has BP below 160/100mmHg (as
measured by office BP), he may have his medication sus-
pended for 2 weeks to confirm the inclusion criteria
(washout phase).
Exclusion criteria:
 Low life expectancy
 Other indications for the use of diuretics
 Intolerance or contraindications to the study drugs
 Cardiovascular disease (heart failure, myocardial
infarction or stroke)
 Secondary hypertension
 Chronic kidney disease and/or abnormal renal
function (creatinine > 1.5 mg/dL)
 Hyperkalemia (serum potassium > 5.5 mEq/L)
 Gout
 Previous antihypertensive treatment with more than
one drug
 Systolic BP ≥ 160 mmHg or diastolic BP ≥ 100
mmHg measured through office BP




The trial has a factorial design, where participants will
receive two simultaneous interventions: a thiazide diur-
etic (CTD 25mg or HCTZ 50mg) and a potassium-
sparing diuretic (amiloride 10mg or amiloride 20 mg).
Participants will be randomly assigned to four parallel
groups:
 CTD 25mg + amiloride 10 mg
 CTD 25mg + amiloride 20 mg
 HCTZ 50mg + amiloride 10 mg
 HCTZ 50mg + amiloride 20 mg
The thiazide diuretic and amiloride will be combined
in a single capsule, which will be provided by a com-
pounding pharmacy. The medication will be adminis-
tered as fixed-dose combinations. Patients will be
instructed to take the medication orally in the morning
upon waking. Adherence to trial medication will be
assessed by means of pill count.
See Additional file 1 for the Template for Intervention
Description and Replication (TIDieR) checklist.
Outcomes
Primary outcomes:
 Difference between the treatment arms in mean
change from baseline in 24-h systolic and diastolic
BP measured by ABPM at 12 weeks
Secondary outcomes:
 Difference between the treatment arms in mean
change from baseline to 12 weeks in: daytime and
nighttime systolic and diastolic BP measured by
ABPM; systolic and diastolic BP measured by office
BP; laboratory parameters.
 Difference between treatment arms in the
proportion of participants reporting adverse events
in the 12 weeks following randomization.
 Difference between treatment arms in the
proportion of participants achieving BP control at
12 weeks. BP control will be defined as < 140/90
mmHg and < 130/80 mmHg for office BP and 24-h
ABPM, respectively.
Participant timeline
Participants will be recruited from outpatient clinics and
from Basic Health Units (public health system) in Porto
Alegre, Brazil, and then invited to participate in the
study.
The first visit will consist of (1) informed consent sign-
ing, (2) eligibility assessment, and (3) sociodemographic
and clinic data collection. If the patient is taking an
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antihypertensive drug and has BP below 160/100 mmHg
(as measured by office BP), he will have his medication
suspended for 2 weeks to confirm the eligibility criteria
(washout phase, which allows most of the effects of the
BP drug to vanish). If no antihypertensive medication is
being used, BP measurements will be carried out in the
office (average of three measurements) and ABPM will
be placed. Then, participants will be instructed to return
the next day after fasting (12 h) for laboratory tests.
The next visit will consist of removal of ABPM, con-
firmation of primary hypertension through ABPM (mean
24-h systolic BP ≥ 130mmHg or mean 24-h diastolic BP
≥ 80mmHg), office BP measurement (average of three
measurements), anthropometric evaluation, and labora-
tory tests. After confirming the eligibility criteria,
randomization and delivery of the study drug will be
performed.
The intermediate visit (week 6) will consist of office
BP measurement (average of three measurements),
evaluation of adherence to treatment, investigation of
adverse events, and delivery of study medication.
Participants will be instructed to return in 6 weeks after
fasting (12 h) for laboratory tests.
The close-out visit (week 12) will consist of office BP
measurement (average of three measurements), an-
thropometric evaluation, evaluation of adherence to
treatment, investigation of adverse events, laboratory
tests, and placement of ABPM. Participants will be
instructed to return the next day for removal of ABPM,
verification of laboratory test results, and termination of
study participation.
The schedule of enrollment, interventions, and assess-
ments is presented in Fig. 1. The allocation of partici-
pants and timeline are presented in Fig. 2.
Sample size
For an absolute difference of 6 mmHg in systolic BP on
24-h ABPM, with an alpha of 0.05, power of 80%, and
standard deviation of 9 mmHg, it will be necessary to
study 76 patients in total. The sample size will be in-
creased by 10% to account for possible losses in follow-
Fig. 1 Schedule of enrollment, interventions and assessments. ABPM ambulatory blood pressure monitoring, BP blood pressure
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up, resulting in 84 patients being randomized (42 for
each arm).
Recruitment
Participants will be recruited from outpatient clinics in
HCPA and Instituto de Cardiologia do Rio Grande do Sul,
Brazil, and from Basic Health Units (public health system).
Patients potentially eligible for the study will be contacted
by telephone by the trial investigator, who will explain the
study and ascertain the patient’s interest. If interested, the
patient will be seen in the Center for Clinical Research of
HCPA, where the study consultations will be made. The
enrollment period is expected to extend over 24months.
Allocation
A computer-generated sequence created by the Random
Allocation Software [35] will be used to randomly assign
patients to the four interventions, stratified by 24-h sys-
tolic BP on ABPM (< 140 or ≥ 140mmHg), with a 1:1:1:1
allocation using random block sizes to generate equal allo-
cation ratio and parallel groups. The block sizes will not
be disclosed, to ensure concealment. The randomization
process will be performed before the beginning of the trial,
with the random allocation sequence registered in Re-
search Electronic Data Capture (REDCap) [36]. To guar-
antee concealment of the allocation list, randomization
will be implemented through a web-based automated
Fig. 2 Allocation of participants and timeline. ABPM ambulatory blood pressure monitoring, BP blood pressure
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system. All patients who give consent for participation
and who fulfill the inclusion criteria will be randomized.
An independent researcher not involved in the enrolment
will produce the randomization sequence. The research
team will be blinded to the randomization sequence and it
will be concealed from the researchers enrolling and
assessing participants. The interventions will be delivered
by researchers with extensive knowledge of the study
medication.
Blinding
The study medication in all groups will have the same
color, taste, consistency, odor, and appearance. In this
way, patients, care providers, outcome assessors, and the
entire research team will be blinded regarding the alloca-
tion to treatment groups throughout the study. Unblind-
ing will occur only when knowledge of the actual
treatment is absolutely essential for further management
of the patient, particularly in the occurrence of serious
adverse events.
Data collection
The research team will be trained to perform anthropo-
metric and BP measurements as well as the application
of questionnaires. A laboratory technician will collect
blood samples after 12-h fasting. These samples will be
forwarded for analysis and discarded shortly after. No
biological specimens will be stored for future studies.
Study data will be collected and managed using REDCap
tools hosted at HCPA.
Anthropometric measurements
The following anthropometric measurements will be col-
lected at baseline and close-out visit: body weight,
height, waist circumference, and body mass index (BMI).
Body weight and height, measured by anthropometric
scales, will be used to calculate the body mass index
(BMI) using the formula BMI =Weight (kg)/Height
squared (m2). BMI values of 18.5 to 24.9 kg/m2 are con-
sidered eutrophic values, while individuals with BMI
values of 25.0 to 29.9 kg/m2 are overweight and ≥ 30 kg/
m2 are obese. The waist circumference, measured at the
midpoint between the iliac crest and the lower costal
margin, is the most representative anthropometric index
of intra-abdominal fat and the simplest reproducible
measurement.
Office blood pressure
Office blood pressure (OBP) will be measured at all
visits with the participant sitting quietly in a chair with
feet on the floor, back supported, and arm resting on a
desk for > 5 min, according to standardized guidelines
[37]. The patient should avoid caffeine, exercise, and
smoking for at least 30 min before measurement. The
cuff size will be used according to arm circumference.
Three measurements will be taken (separated by 1–2
min) with a validated automatic oscillometric BP meas-
uring device (HBP-1100, OMRON Healthcare) and the
average recorded. Baseline OBP and final OBP will be
considered as the mean of six measurements in two sep-
arate visits.
24-h ABPM
ABPM is a method that allows the indirect and intermit-
tent recording of BP for 24-h while patients perform
their usual activities during the day. Monitoring requires
patients to maintain their normal daily activities with
the BP being measured automatically at 15 min intervals
(daytime) and 20 min intervals (nighttime) for an entire
24-h period. The systolic BP and diastolic BP will be ob-
tained by ABPM, with the mean values for the 24-h
period, daytime, and nighttime being considered for ana-
lysis. The normal nocturnal dip will be defined as a drop
of > 10% in systolic BP from wakefulness to the period
of sleeping. Participants will be evaluated by ABPM at
the baseline and at the end of the follow-up. ABPM will
be performed using portable monitors (Spacelabs 90,207,
Redmond, WA, USA).
Laboratory tests
Blood samples will be drawn from all patients at the first
and last visits after fasting for 12 h. The following la-
boratory parameters will be assessed: serum total choles-
terol (TC), HDL cholesterol (HDL-C), LDL cholesterol
(LDL-C), triglycerides (TG), creatinine, urea, potassium,
sodium, magnesium, uric acid, fasting plasma glucose,
and hemoglobin A1c (HbA1c). The LDL fraction is cal-
culated in mg/dL, using the Friedewald formula [LDL =
TC −HDL −TG/5 (for TG < 400mg/dL)].
Adverse events
Patients will be interviewed at each visit about the oc-
currence of any adverse events using open questions and
a semi-structured questionnaire, including time of onset,
duration, and severity; all information will be recorded
on an electronic case report form (eCRF). The causal re-
lation to the study drug and the intensity of adverse
events will be evaluated by the investigators. Serious ad-
verse events (SAE) must be reported to the institutional
review board by the principal investigator within 24 h
after the SAE becomes known. Laboratory adverse
events, such as hypokalemia, hyperuricemia, and hyper-
glycemia will be investigated at the final visit.
To improve participant retention, study researchers
will make efforts to monitor patients during the study
period, including telephone reminders for upcoming
visits. Telephone calls will be made to inquire about ad-
verse events if a participant misses a scheduled visit.
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Furthermore, all participants will be requested to
promptly report possible adverse events by telephone.
The participant will be advised on the importance of ad-
hering to the treatment protocol not only for validation
of the study results, but mainly for their safety and pos-
sible health benefits. In order to improve adherence to
intervention protocols, we will use pill count to monitor
patient compliance. Participants can withdraw from the
trial at any time for any reason without their medical
care being affected. Data already collected will continue
to be used, and the patients will be asked if they are still
willing to provide follow-up data. The reason for with-
drawal will be documented whenever possible.
Data collection forms
Study data will be collected and managed using REDCap
tools hosted at HCPA. REDCap is a secure, web-based
application designed to support data capture for research
studies, providing: 1) an intuitive interface for validated
data entry; 2) audit trails for tracking data manipulation
and export procedures; 3) automated export procedures
for seamless data downloads to common statistical pack-
ages; and 4) procedures for importing data from external
sources. An eCRF will be constructed for data registra-
tion. Data integrity will be enforced through valid values
and range checks. For data analysis, subject-related data
from REDCap will be exported and analyzed in statistics
software (IBM SPSS). Before data export, all patient
identifiers will be removed.
Data management
Each participant will be given an identification number
at enrolment, and each identification number will have
an eCRF. The list over identification codes will be de-
leted at the end of the study. All trial data, including
Trial Master File, eCRF, the source datasheet of the
eCRF, and the list of identification codes will be stored
in the external server of REDCap with continuous
backup. REDCap data are kept for 10 years. Study-
related patient documentation and the signed informed
consent form will be stored in a patient-specific folder.
Statistical methods
All data will be analyzed according to the intention-to-
treat principle, considering all patients as randomized
regardless of whether they received the randomized
treatment. Analyses will be performed with the software
SPSS for Windows (version 17; SPSS Inc., Chicago, Illi-
nois, USA). A P value < 0.05 will be considered statisti-
cally significant.
The sample characteristics will be presented by de-
scriptive statistics, and the results will be expressed as
mean, standard deviation, and percentage. The compari-
son of levels of BP among treatment groups at each visit
will be done using a t-test for independent samples, and
a random-effects linear model fitted to systolic and dia-
stolic BP will be used to compare BP by treatment group
during follow-up. The random-effects model will include
an intercept and a slope to adjust for the within-
participant correlation among the longitudinal data with
test for interaction. An attempt to measure BP at the
end of trial even for participants that abandoned the
treatment will be undertaken. The cumulative incidence
of adverse events will be analyzed by Chi-square test.
Adverse events will be reported with relative risk and
95% confidence intervals. No subgroup or adjusted ana-
lyses are planned for this study.
Assuming there will be no interaction between thia-
zides and amiloride, we intend to carry out pooled ana-
lysis of the differences between CTD (CTD 25mg with
amiloride 10mg and CTD 25mg with amiloride 20 mg)
versus HCTZ (HCTZ 50mg with amiloride 10mg and
HCTZ 50mg with amiloride 20 mg) and the differences
between amiloride in a lower dose (amiloride 10mg with
CTD 25mg and amiloride 10mg with HCTZ 50mg)
versus amiloride in a higher dose (amiloride 20mg with
CTD 25mg and amiloride 20mg with HCTZ 50mg).
Data monitoring
Due to the short duration of the trial and minimal risks
associated with the interventions, a Data Monitoring
Committee will not be established, and interim analyses
will not be performed. Committees involved in trial co-
ordination and conduct are to be decided elsewhere and
will be described in amendments or in the final text.
Harms
At all follow-up visits, adverse events will be investigated
by spontaneous reporting and by a directed question-
naire. An adverse event is considered to be any un-
desired medical occurrence in a clinical trial participant
who has received a pharmaceutical product, even if it
does not necessarily have a causal relationship to that
treatment. A severe adverse event is considered to be
any unfavorable medical occurrence that results in
death, threat to life, hospitalization or its prolongation,
or persistent or significant disability. The causal relation-
ship to the study drug and the intensity of adverse
events will be evaluated by the investigators. The com-
munication of adverse events classified as severe or un-
expected will be reported to the Ethics Committee. SAE
must be reported by the principal investigator within 24-
h after the SAE becomes known. The participant who
presents with a severe adverse event will be withdrawn
from the study. Withdrawal may also occur in the event
of intolerance of the participant to non-severe adverse
events. In this case, the procedures for the last visit will
be carried out. Laboratory adverse events, such as
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hypokalemia, hyperuricemia, and hyperglycemia, will be
investigated at the final visit. All adverse events and
withdrawals due to adverse events will be reported, irre-
spective of severity, with no frequency threshold.
Auditing
A quality assurance audit/inspection of this study may
be conducted by the competent authority. The quality
assurance auditor/inspector will have access to all med-
ical records, the investigator’s study related files and cor-
respondence, and the informed consent documentation
that is relevant to this clinical study. The investigator
will allow the persons being responsible for the audit or
the inspection to have access to the source data/docu-
ments and to answer any questions arising. All involved
parties will keep the patient data strictly confidential.
Standard Protocol Items: Recommendations for
Interventional Trials checklist
This article followed the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) 2013 state-
ment on the writing of a study protocol for a clinical trial
[38]. The filled SPIRIT checklist can be found in Add-
itional file 2. The World Health Organization Trial Regis-
tration Data Set is provided in Additional file 3.
Protocol amendments
Any modifications to the protocol which may impact on
the conduct of the study or potential benefit to the pa-
tient or may affect patient safety, including changes of
study objectives, study design, patient population, sam-
ple sizes, study procedures, or significant administrative
aspects, will require a formal amendment to the proto-
col. Such amendments will be approved by the Ethics
Committee of HCPA prior to implementation. Amend-
ments will be disclosed in the new version of the proto-
col with reasons.
Consent
Trained physicians responsible for eligibility will supply
informed consent forms to patients willing to participate
in the trial. The consent form includes institutional af-
filiation, the objectives of the study, a description of the
testing procedures, explanation about interventions and
its randomized allocation nature, information about ex-
pected length of time for participation, the potential
risks and benefits involved in the study, the costs to the
participants, information on anonymized data sharing,
and an explanation of the patient’s right to refuse par-
ticipation or to withdraw consent at any time. A copy of
the consent form is given to the participant, and this fact
is documented in the subject’s record. The investigator
in charge of providing clarification on the study and
seeking the participant’s ethical consent must allow the
subject sufficient time to decide whether or not to par-
ticipate in the trial. Once a subject decides to participate,
a signed and personally dated informed consent form is
obtained from the subject before any trial-related pro-
cedure. As there are no plans for use of data from this
trial in ancillary studies, no additional consent will be
required.
Confidentiality
Study data will be collected and managed using REDCap
tools. All laboratory specimens, reports, data collection,
processes, and administrative forms will be identified by
a coded identification number to maintain participant
confidentiality. After full data analysis, all subject identi-
fiers will be erased. The principal investigator will grant
the relevant personnel user rights to view, edit, or over-
write data entries by password as applicable. All edits
will be automatically documented in the change history
log. Direct access to source data may be granted in the
case of monitoring, audit, or inspections. All personnel
must treat patient data as confidential. As far as possible,
encoded data will be used.
Access to data
All trial investigators will be given access to the cleaned
data sets. Project data sets will be stored in the external
server of REDCap hosted at HCPA, and all data sets will
be password protected. To ensure confidentiality, data
dispersed to project team members will be blinded of
any identifying participant information.
Ancillary and post-trial care
The study drugs have been used for a long time to treat
hypertension and are considered safe. The risks of the
study are mainly due to the possibility of adverse effects
with the drugs. The most frequent adverse effects are
anorexia, dyspepsia, dizziness, headache, cramps, and
increased urine volume, and usually do not require dis-
continuation of treatment. In case of adverse effects or
problems related to participation in the study that require
medical treatment, the investigators will be responsible for
the care such that participant do not incur costs.
Discussion
Thiazide diuretics have good tolerability and proven BP-
lowering efficacy, although there is concern about meta-
bolic complications with these agents (e.g., hypokal-
emia), which can be mitigated by the association of a
potassium-sparing diuretic, such as amiloride. This is
the first double-blind, randomized controlled trial com-
paring CTD versus HCTZ combined with amiloride in
different doses in relation to BP-lowering efficacy and
adverse metabolic effects in patients with primary hyper-
tension. Although the primary outcome (change from
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baseline in BP) is not a clinical endpoint, BP has been a
valid surrogate of the beneficial effects of BP-lowering
drugs. Thus, by identifying the diuretic treatment with
greater antihypertensive efficacy and lower incidence of
adverse effects, this study will provide evidence-based in-
formation that could help in the accomplishment of a
more effective hypertension treatment.
Trial status
This is the first version of the protocol (issue date 28
June 2019). The study has not started recruiting partici-
pants. We anticipate the study will start by November
2019 and be completed by November 2021.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3909-z.
Additional file 1. TIDieR checklist.
Additional file 2. SPIRIT 2013 checklist: Recommended items to address
in a clinical trial protocol and related documents.
Additional file 3. World Health Organization Trial Registration Data Set.
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